Log in

Relevant bibliographies by topics / Beta 2-glycoprotein I / Journal articles

To see the other types of publications on this topic, follow the link: Beta 2-glycoprotein I.

Journal articles on the topic 'Beta 2-glycoprotein I'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Beta 2-glycoprotein I.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Inanc, M. "beta 2-Glycoprotein I and anti-beta 2-glycoprotein I antibodies: where are we now?" Rheumatology 36, no. 12 (December 1, 1997): 1247–57. http://dx.doi.org/10.1093/rheumatology/36.12.1247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Schousboe, I. "beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway." Blood 66, no. 5 (November 1, 1985): 1086–91. http://dx.doi.org/10.1182/blood.v66.5.1086.1086.

Full text

Abstract:

Abstract The general hypothesis for the biological function of beta 2- glycoprotein I is that it neutralizes all negatively charged macromolecules that might enter the bloodstream and diminishes unwanted activation of the blood coagulation. In the present study we report that beta 2-glycoprotein I inhibits the activation of the contact phase system of the intrinsic pathway of blood coagulation. Activation was accomplished by an ellagic acid-phospholipid suspension (Cephotest) and measured by the appearance of amidolytic activity using the chromogenic substrate H-D-Pro-Phe-Arg-p-nitroanilide (S

APA, Harvard, Vancouver, ISO, and other styles

3

Schousboe, I. "beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway." Blood 66, no. 5 (November 1, 1985): 1086–91. http://dx.doi.org/10.1182/blood.v66.5.1086.bloodjournal6651086.

Full text

Abstract:

The general hypothesis for the biological function of beta 2- glycoprotein I is that it neutralizes all negatively charged macromolecules that might enter the bloodstream and diminishes unwanted activation of the blood coagulation. In the present study we report that beta 2-glycoprotein I inhibits the activation of the contact phase system of the intrinsic pathway of blood coagulation. Activation was accomplished by an ellagic acid-phospholipid suspension (Cephotest) and measured by the appearance of amidolytic activity using the chromogenic substrate H-D-Pro-Phe-Arg-p-nitroanilide (S-2302). T

APA, Harvard, Vancouver, ISO, and other styles

4

Arad, Ariela, Richard A. Furie, Barbara C. Furie, and Bruce Furie. "Affinity-Purified Anti-Beta-2 Glycoprotein-1 Antibodies from a Patient with Lupus Anticoagulant-Associated Thrombosis Amplify Thrombus Formation in the Living Mouse." Blood 114, no. 22 (November 20, 2009): 146. http://dx.doi.org/10.1182/blood.v114.22.146.146.

Full text

Abstract:

Abstract Abstract 146 Antiphospholipid syndrome (APS) is characterized by thrombosis, recurrent fetal loss and the presence of the lupus anticoagulant, anticardiolipin antibodies or anti-beta-2 glycoprotein 1 antibodies. Sera from patients with APS contain polyclonal antibodies that bind to various plasma proteins including beta-2 glycoprotein 1. Although beta-2 glycoprotein 1 antibodies have been well-documented as a biomarker for the diagnosis of APS, their direct role in the pathogenesis of thrombosis is unknown. Here, we have demonstrated using intravital microscopy that purified anti-beta

APA, Harvard, Vancouver, ISO, and other styles

5

Kertesz, Z., B. B. Yu, A. Steinkasserer, H. Haupt, A. Benham та R. B. Sim. "Characterization of binding of human β2-glycoprotein I to cardiolipin". Biochemical Journal 310, № 1 (15 серпня 1995): 315–21. http://dx.doi.org/10.1042/bj3100315.

Full text

Abstract:

beta 2-Glycoprotein I-cardiolipin complexes are reported to be a target antigen for the binding of a subset of anti-phospholipid antibodies. The characteristics of binding of beta 2-glycoprotein I to cardiolipin are reported in this paper. Binding at neutral pH is specific, saturable, dependent on ionic strength and independent of bivalent cation. Binding at low pH is qualitatively different from that at neutral pH, and is not dependent on ionic strength. Denaturation of beta 2-glycoprotein I by heat inactivation and reduction/alkylation indicates that beta 2-glycoprotein I-cardiolipin interac

APA, Harvard, Vancouver, ISO, and other styles

6

Wittevrongel, C., M. Vanrusselt, M. Hoylaerts, J. Vermylen, and J. Arnout. "Beta-2-glycoprotein I Dependent Lupus Anticoagulants Form Stable Bivalent Antibody Beta-2-Glycoprotein I Complexes on Phospholipid Surfaces." Thrombosis and Haemostasis 79, no. 01 (1998): 79–86. http://dx.doi.org/10.1055/s-0037-1614224.

Full text

Abstract:

SummaryThe precise mechanism by which Beta-2-glycoprotein I (β2GPI-) dependent lupus anticoagulants lengthen phospholipid-dependent clotting reactions is still poorly understood. In order to study this, murine monoclonal antibodies (moabs) against human β2GPI were raised. Eight of the 21 anti-β2GPI moabs, obtained from 2 fusions, fulfilled the criteria for lupus anticoagulant (LA) activity as tested with a variety of sensitive screening assays and confirmatory tests. Seven moabs did not influence any clotting test. The LA positive moabs were found to compete for similar or closely spaced epito

APA, Harvard, Vancouver, ISO, and other styles

7

Marai, Ibrahim, Angela Tincani, Genesio Balestrieri, and Yehuda Shoenfeld. "Anticardiolipin and anti-beta-2-glycoprotein I antibodies." Autoimmunity 38, no. 1 (February 2005): 33–38. http://dx.doi.org/10.1080/08916930400022608.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Božič, B., S. Čučnik, T. Kveder, and B. Rozman. "Avidity of anti-beta-2-glycoprotein I antibodies." Autoimmunity Reviews 4, no. 5 (June 2005): 303–8. http://dx.doi.org/10.1016/j.autrev.2005.01.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Meroni, P. L., D. Mari, D. Monti, R. Coppola, M. Capri, S. Salvioli, A. Tincani, R. Gerli, and C. Franceschi. "Anti-beta 2 glycoprotein I antibodies in centenarians." Experimental Gerontology 39, no. 10 (October 2004): 1459–65. http://dx.doi.org/10.1016/j.exger.2004.08.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Matsuda, J., N. Saitoh, M. Gotoh, K. Gohchi, and M. Tsukamoto. "Prevalence of beta 2-glycoprotein I antibody in systemic lupus erythematosus patients with beta 2-glycoprotein I dependent antiphospholipid antibodies." Annals of the Rheumatic Diseases 54, no. 1 (January 1, 1995): 73–75. http://dx.doi.org/10.1136/ard.54.1.73.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Brochado, Maria José Franco, José Fernando C. Figueiredo, Celso Teixeira Mendes-Junior, Paulo Louzada-Junior, Olivia Makiyama Kim, and Ana Maria Roselino. "Correlation between beta-2-glycoprotein I gene polymorphism and anti-beta-2 glycoprotein I antibodies in patients with multibacillary leprosy." Archives of Dermatological Research 302, no. 8 (February 7, 2010): 583–91. http://dx.doi.org/10.1007/s00403-010-1032-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

KABURAKI, Junichi, Masataka KUWANA, Mihoko YAMAMOTO, Shinichi KAWAI, Eiji MATSUURA, and Yasuo IKEDA. "Phospholipid-Dependent Anti-.BETA.2-Glycoprotein I (.BETA.2-GPI) Antibodies and Antiphospholipid Syndrome." Internal Medicine 35, no. 2 (1996): 105–10. http://dx.doi.org/10.2169/internalmedicine.35.105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Norden, A. G. W., L. M. Fulcher, M. Lapsley, and F. V. Flynn. "Excretion of beta 2-glycoprotein I (apolipoprotein H) in renal tubular disease." Clinical Chemistry 37, no. 1 (January 1, 1991): 74–77. http://dx.doi.org/10.1093/clinchem/37.1.74.

Full text

Abstract:

Abstract beta 2-Glycoprotein I (beta 2GI) was identified as a major urinary protein excreted by patients with several renal tubular diseases, including adult Fanconi syndrome, nephrocalcinosis associated with autoimmune diseases, Lowe's syndrome, and Dent's disease (a familial renal tubular disease). Sixteen patients excreted between 2 and 40 mg of beta 2GI per millimole of creatinine. In contrast, 18 healthy controls had undetectable amounts of beta 2GI in urine. Isoelectric focusing followed by immunoblotting demonstrated multiple forms of beta 2GI with pls between 6.4 and 8.2. These pls are

APA, Harvard, Vancouver, ISO, and other styles

14

Nakagawa, Hisako, Shinsuke Yasuda, and Tadaaki Miyazaki. "Novel Function of Beta 2 Glycoprotein I in Angiogenesis." Current Angiogenesis 3, no. 3 (March 11, 2015): 132–38. http://dx.doi.org/10.2174/2211552803666141125214938.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Miyakis, Spiros, Bill Giannakopoulos, and Steven A. Krilis. "Beta 2 glycoprotein I-function in health and disease." Thrombosis Research 114, no. 5-6 (January 2004): 335–46. http://dx.doi.org/10.1016/j.thromres.2004.07.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

EBELING, F., T. PETTERSSON, L. MUUKKONEN, E. VAHTERA, and V. RASI. "Beta‐2‐glycoprotein I antibodies in patients with thrombosis." Scandinavian Journal of Clinical and Laboratory Investigation 63, no. 2 (January 2003): 111–18. http://dx.doi.org/10.1080/00365510310002086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Blanco, Manuel Serrano, Jose Angel KJA Martinez Flores 2, Dolores Perez, Jose Maria Morales, Javier Gainza, Roberto Marcen, Fernando Escuin, et al. "Pre-transplant antibodies IgA-anti Beta 2 Glycoprotein I." Transplantation 102, Supplement 7 (July 2018): S189. http://dx.doi.org/10.1097/01.tp.0000542834.31485.ac.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Balasubramanian, Krishnakumar, Jerald J. Killion, and Alan J. Schroit. "Estimation of Plasma Beta-2-Glycoprotein Levels by Competitive ELISA." Thrombosis Research 92, no. 2 (October 1998): 91–97. http://dx.doi.org/10.1016/s0049-3848(98)00115-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Brusch, Anna M. "Antiphospholipid antibodies: significance of anti-beta-2-glycoprotein i isotypes." Pathology 47 (2015): S40. http://dx.doi.org/10.1097/01.pat.0000461431.82122.d7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Artusi, C., S. Fumagalli, M. Oggioni, M. O. Borghi, C. Grossi, P. L. Meroni, F. Tedesco, and M. G. De Simoni. "AB0131 Tissue Beta 2 glycoprotein I in Brain Ischemic Injury." Annals of the Rheumatic Diseases 75, Suppl 2 (June 2016): 941.3–941. http://dx.doi.org/10.1136/annrheumdis-2016-eular.5315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Blank, Miri, and Yehuda Shoenfeld. "Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations." Clinical Immunology 112, no. 2 (August 2004): 190–99. http://dx.doi.org/10.1016/j.clim.2004.02.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Passam, F. H., J. C. Qi, K. Tanaka, K. I. Matthaei, and S. A. Krilis. "In vivo modulation of angiogenesis by beta 2 glycoprotein I." Journal of Autoimmunity 35, no. 3 (November 2010): 232–40. http://dx.doi.org/10.1016/j.jaut.2010.06.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ebeling, Freja, Jari Pet�j�, Soile Alanko, Aune Hirvasniemi, Tarja Holm, Marja L�hde, Auli Nuutila, Helena Pesonen, Elina Vahtera, and Vesa Rasi. "Infant stroke and beta-2-glycoprotein 1 antibodies: six cases." European Journal of Pediatrics 162, no. 10 (October 1, 2003): 678–81. http://dx.doi.org/10.1007/s00431-003-1285-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Passam, Freda H., Soheila Rahgozar, Miao Qi, Mark J. Raftery, Jason W. H. Wong, Kumiko Tanaka, Yiannis Ioannou, et al. "Beta 2 glycoprotein I is a substrate of thiol oxidoreductases." Blood 116, no. 11 (September 16, 2010): 1995–97. http://dx.doi.org/10.1182/blood-2010-02-271494.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Roberts, G. P. "Characterization of the antigens recognized by two monoclonal antibodies reactive with basal-layer keratinocytes of human epidermis." Biochemical Journal 299, no. 3 (May 1, 1994): 659–64. http://dx.doi.org/10.1042/bj2990659.

Full text

Abstract:

Two monoclonal antibodies, GR3 and GR4, reactive with the basal-layer keratinocytes of human epidermis, were derived by immunization of Balb/c mice with glycoproteins isolated from cultured keratinocytes by lectin-affinity chromatography. Immunoprecipitation of Triton X-100 extracts from human keratinocytes metabolically labelled with D-[1-14C]glucosamine revealed that GR3 recognized a major glycoprotein with migration properties identical with those of a glycoprotein (reduced form M(r) 126,000) which was previously shown to be implicated in intercellular adhesion [Roberts and Brunt (1985) Bio

APA, Harvard, Vancouver, ISO, and other styles

26

Joneckis, CC, RL Ackley, EP Orringer, EA Wayner, and LV Parise. "Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia." Blood 82, no. 12 (December 15, 1993): 3548–55. http://dx.doi.org/10.1182/blood.v82.12.3548.3548.

Full text

Abstract:

Abstract The abnormal adherence of red blood cells, especially circulating reticulocytes (erythrocyte precursors), to the endothelium is believed to contribute to vascular occlusion observed in patients with sickle cell disease. Although several plasma proteins including von Willebrand factor and fibronectin have been proposed to mediate this adhesion, the mechanism of sickle cell adhesion to the endothelium remains unknown. Using flow cytometry, we screened sickle red blood cells with monoclonal antibodies (MoAbs) against known adhesion receptors and detected integrin subunits alpha 4 and bet

APA, Harvard, Vancouver, ISO, and other styles

27

Joneckis, CC, RL Ackley, EP Orringer, EA Wayner, and LV Parise. "Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia." Blood 82, no. 12 (December 15, 1993): 3548–55. http://dx.doi.org/10.1182/blood.v82.12.3548.bloodjournal82123548.

Full text

Abstract:

The abnormal adherence of red blood cells, especially circulating reticulocytes (erythrocyte precursors), to the endothelium is believed to contribute to vascular occlusion observed in patients with sickle cell disease. Although several plasma proteins including von Willebrand factor and fibronectin have been proposed to mediate this adhesion, the mechanism of sickle cell adhesion to the endothelium remains unknown. Using flow cytometry, we screened sickle red blood cells with monoclonal antibodies (MoAbs) against known adhesion receptors and detected integrin subunits alpha 4 and beta 1 and t

APA, Harvard, Vancouver, ISO, and other styles

28

Buchholz, Ina, Peter Nestler, Susan Köppen, and Mihaela Delcea. "Lysine residues control the conformational dynamics of beta 2-glycoprotein I." Physical Chemistry Chemical Physics 20, no. 42 (2018): 26819–29. http://dx.doi.org/10.1039/c8cp03234c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Gao, Pu-Jun. "Studies on specific interaction of beta-2-glycoprotein I with HBsAg." World Journal of Gastroenterology 9, no. 9 (2003): 2114. http://dx.doi.org/10.3748/wjg.v9.i9.2114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Balestrieri, Genesio, Angela Tincani, Laura Spatola, Flavio Allegri, Enrica Prati, Roberto Cattaneo, Guido Valesini, Nicoletta Del Papa, and Pierluigi Meroni. "Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?" Lupus 4, no. 2 (April 1995): 122–30. http://dx.doi.org/10.1177/096120339500400208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Wong, R. C. W., E. J. Favaloro, S. Adelstein, K. Baumgart, R. Bird, T. A. Brighton, M. Empson, et al. "Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting." Pathology 40, no. 1 (January 2008): 58–63. http://dx.doi.org/10.1080/00313020701717720.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Abinader, A., A. J. Hanly, and C. J. Lozada. "Catastrophic antiphospholipid syndrome associated with anti-beta-2- glycoprotein I IgA." Rheumatology 38, no. 1 (January 1, 1999): 84–85. http://dx.doi.org/10.1093/rheumatology/38.1.84.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Fiallo, Paolo, Carlo Tomasina, Andrea Clapasson, and Paolo P. Cardo. "Antibodies to Beta₂-Glycoprotein I in Ischemic Stroke." Cerebrovascular Diseases 10, no. 4 (2000): 293–97. http://dx.doi.org/10.1159/000016073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Fleming, Sherry D. "Beta 2-glycoprotein I derived-peptides attenuate complement-mediated intestinal damage." Immunobiology 217, no. 11 (November 2012): 1141. http://dx.doi.org/10.1016/j.imbio.2012.08.035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Antosik, P., B. Kempisty, M. Jackowska, D. Bukowska, M. Lianeri, KP Brussow, and M. Wozna. "The morphology of porcine oocytes is associated with zona pellucida glycoprotein 3 and integrin beta 2 protein levels--." Veterinární Medicína 55, No. 4 (May 19, 2010): 154–62. http://dx.doi.org/10.17221/38/2010-vetmed.

Full text

Abstract:

The morphology and quality of oocytes is set during oo- and folliculo-genesis, and is completed during final maturation. Early embryonic development is associated with the morphology of the cumulus-oocyte-complex (COC). However, current knowledge of the possible relationships between oocyte morphology and the level of proteins within the oocyte, which may reflect fertilization ability, is insufficient. Using western-blot analysis and confocal microscopic observation, we determined the levels of integrin beta-2 (integrin &beta;2) and glycoprotein 3 (pZP3) protein levels in the porcine zona

APA, Harvard, Vancouver, ISO, and other styles

36

Gries, A., J. Nimpf, H. Wurm, G. M. Kostner та T. Kenner. "Characterization of isoelectric subspecies of asialo-β2-glycoprotein I". Biochemical Journal 260, № 2 (1 червня 1989): 531–34. http://dx.doi.org/10.1042/bj2600531.

Full text

Abstract:

Isoelectric focusing of purified beta 2-glycoprotein I (beta 2-G-I) revealed five major bands with isoelectric points (pI) between 5.1 and 6.1. Neuraminidase treatment decreased the number of bands to two (pI 8.0 and 8.2). The two asialo subfractions of beta 2-G-I were purified by cation-exchange column chromatography. The more basic isoform II was found to have a higher content of lysine. Western-blot analysis of different plasma samples confirmed the heterogeneity of beta 2-G-I in plasma. Plasma treated with neuraminidase showed two bands irrespective of the number of isoforms as well as of

APA, Harvard, Vancouver, ISO, and other styles

37

Donald, A. S. R., and J. Feeney. "Oligosaccharides obtained from a blood-group-Sd(a+) Tamm-Horsfall glycoprotein. An n.m.r. study." Biochemical Journal 236, no. 3 (June 15, 1986): 821–28. http://dx.doi.org/10.1042/bj2360821.

Full text

Abstract:

Treatment of Tamm-Horsfall urinary glycoprotein with Bacteroides fragilis endo-beta-galactosidase over a range of enzyme concentrations, pH and temperature resulted in the release of a small but constant proportion of the terminal sugars, which indicates the presence in the glycoprotein of relatively few enzyme-susceptible -GlcNAc beta 1-3Gal beta 1-4GlcNAc- units. Three oligosaccharides were isolated from the enzyme digest and characterized as Gal beta 1-4GlcNAc beta 1-3Gal, NeuAc alpha 2-3Gal beta 1-4 GlcNAc beta 1-3Gal and GalNAc beta 1-4(NeuAc alpha 2-3)Gal beta 1-4GlcNAc beta 1-3Gal by me

APA, Harvard, Vancouver, ISO, and other styles

38

TAKAMATSU, Kazunaga, Tadashi SUEHIRO, Masui KAWADA, and Fumitoshi OHNO. "Clinical Studies on Apolipoprotein H (β₂-glycoprotein I) in Patients with Hyperlipoproteinemia." Journal of Japan Atherosclerosis Society 15, no. 6 (1987): 1401–8. http://dx.doi.org/10.5551/jat1973.15.6_1401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Brusch, Anna. "The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome." Antibodies 5, no. 2 (June 8, 2016): 16. http://dx.doi.org/10.3390/antib5020016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gang, Yong, Nobuhiko Kubo, Ikunosuke Sakurabayashi, Yoshihiko Ohtsuka, Jun Suzuki, Yasuhiro Nomata, and Tadashi Kawai. "Structural variety and biological function of apolipoprotein H (.BETA.2-glycoprotein I)." SEIBUTSU BUTSURI KAGAKU 38, no. 1 (1994): 1–5. http://dx.doi.org/10.2198/sbk.38.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

BRIGHTON, Timothy A., Yan-Ping DAI, Philip J. HOGG, and Colin N. CHESTERMAN. "Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids." Biochemical Journal 340, no. 1 (May 10, 1999): 59–67. http://dx.doi.org/10.1042/bj3400059.

Full text

Abstract:

Considerable interest is currently focused on the interactions of beta-2 glycoprotein I (β2GPI) and anti-phospholipid antibodies with anionic phospholipids in an attempt to understand the association between these antibodies and clinical diseases such as thrombosis. The interactions of β2GPI and anionic phospholipids have only been characterized partially, and the physiological role of this glycoprotein remains uncertain. In this study we have explored in detail the physical and phospholipid-binding characteristics of a number of β2GPI preparations. We have found (i) that perchloric acid-purif

APA, Harvard, Vancouver, ISO, and other styles

42

Mankaï, A., A. Achour, Y. Thabet, W. Manoubia, W. Sakly, and I. Ghedira. "Anti-cardiolipin and anti-beta 2-glycoprotein I antibodies in celiac disease." Pathologie Biologie 60, no. 5 (October 2012): 291–95. http://dx.doi.org/10.1016/j.patbio.2011.07.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Alarcon, Marcelo, Eduardo Fuentes, Ximena Maldonado, Claudia Mardones, and Iván Palomo. "Methodology of generation and purification of anti-beta 2 glycoprotein I antibodies." MethodsX 6 (2019): 986–92. http://dx.doi.org/10.1016/j.mex.2019.04.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Terashi, Hiromi, Shinichiro Uchiyama, Shiori Hashimoto, and Makoto Iwata. ".BETA.2-glycoprotein I polymorphism as a risk factor for cerebral infarction." Nosotchu 27, no. 4 (2005): 608–11. http://dx.doi.org/10.3995/jstroke.27.608.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

BRIGHTON, Timothy A., Yan-Ping DAI, Philip J. HOGG, and Colin N. CHESTERMAN. "Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids." Biochemical Journal 340, no. 1 (May 15, 1999): 59. http://dx.doi.org/10.1042/0264-6021:3400059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Cabral, A. R., and D. Alarcon-Segovia. "Anti-beta 2-glycoprotein I antibody testing in patients with antiphospholipid syndrome." Rheumatology 36, no. 11 (November 1, 1997): 1235. http://dx.doi.org/10.1093/rheumatology/36.11.1235.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Hasdemir, Hale S., and Emad Tajkhorshid. "Characterization of Beta-2-Glycoprotein I Domain V interaction with Plasma Membrane." Biophysical Journal 120, no. 3 (February 2021): 47a—48a. http://dx.doi.org/10.1016/j.bpj.2020.11.530.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Matsuura, E., Y. Igarashi, T. Yasuda, D. A. Triplett, and T. Koike. "Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface." Journal of Experimental Medicine 179, no. 2 (February 1, 1994): 457–62. http://dx.doi.org/10.1084/jem.179.2.457.

Full text

Abstract:

Anticardiolipin antibodies (aCL) derived from the sera of individuals exhibiting the antiphospholipid syndrome (APS) directly bind to beta 2-glycoprotein I (beta 2-GPI), which is adsorbed to an oxidized polystyrene surface. Oxygen atoms were introduced on a polystyrene surface by irradiation with electron or gamma-ray radiation. X-ray photoelectron spectroscopy revealed the irradiated surfaces were oxidized to generate C-O and C = O moieties. aCL derived from either APS patients or (NZW x BXSB)F1 mice bound to beta 2-GPI coated on the irradiated plates, depending on the radiation dose. Antibod

APA, Harvard, Vancouver, ISO, and other styles

49

Mitchell, E. J., K. Lee, and M. D. O'Connor-McCourt. "Characterization of transforming growth factor-beta (TGF-beta) receptors on BeWo choriocarcinoma cells including the identification of a novel 38-kDa TGF-beta binding glycoprotein." Molecular Biology of the Cell 3, no. 11 (November 1992): 1295–307. http://dx.doi.org/10.1091/mbc.3.11.1295.

Full text

Abstract:

Transforming growth factor-beta (TGF-beta) is a potential mediator of placental trophoblast functions, including differentiation, hormone production, endometrial invasion, and immunosuppression. Equilibrium binding and affinity-labeling assays were used to investigate the binding characteristics of TGF-beta 1 and TGF-beta 2 on an established human choriocarcinoma trophoblastic cell line (BeWo). The equilibrium binding experiments indicated that the BeWo cells exhibited similar average affinities and total number of binding sites for TGF-beta 1 and TGF-beta 2. The Kd values obtained from Scatch

APA, Harvard, Vancouver, ISO, and other styles

50

Atsumi, T., M. Khamashta, P. R. J. Ames, K. Ichikawa, T. Koike, and G. R. V. Hughes. "Protein S, C4b-binding protein (C4BP) and beta 2-glycoprotein I (??2-GPI) binding interaction." Blood Coagulation & Fibrinolysis 6, no. 6 (September 1995): 594. http://dx.doi.org/10.1097/00001721-199509000-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!